Purdue, NorthStar Collaborate on Nuclear Pharmacy Training
Contact Our Team
For more information about how Halldale can add value to your marketing and promotional campaigns or to discuss event exhibitor and sponsorship opportunities, contact our team to find out more
The Americas -
holly.foster@halldale.com
Rest of World -
jeremy@halldale.com
NorthStar Medical Radioisotopes LLC and Purdue University’sCollege of Pharmacy announced a collaborative agreement which expands theCollege of Pharmacy’s nuclear pharmacy training program. As part of thecollaboration, NorthStar has provided a RadioGenix System to the College ofPharmacy for use in training nuclear pharmacy students on the production oftechnetium-99m (Tc-99m), currently the most widely used medical radioisotopefor critical diagnostic imaging tests in the United States. Access to theRadioGenix platform provides nuclear pharmacy students the opportunity to becomefamiliar with the equipment, which uses domestically sourced, non-uraniumtarget material and an environmentally friendly production process to produceTc-99m. As part of its user experience, the College of Pharmacy is providingNorthStar with feedback about the RadioGenix System and early testing ofplanned enhancements.
“We will use theRadioGenix System to provide ‘hands-on’ laboratory-based experiences so thatour student pharmacists have access to the latest advancements in radiopharmacyproduction techniques and are well-equipped for the professional workplace,” saidEric L. Barker, Ph.D. dean, Purdue College of Pharmacy.
“Our relationship with NorthStar has provided our studentswith a unique insight into this exciting new development in nuclear pharmacypractice, and as they move out of academia and begin practice, they are able tobetter understand the pivotal role that a domestic supply of Mo-99 will play inthe future,” said Kara D. Weatherman, PharmD, BCNP, FAPhA, clinical associate professorof Pharmacy Practice, director, Nuclear Pharmacy Programs, Purdue College ofPharmacy. “In addition, our use of the NorthStar RadioGenix System provides astable supply of Mo-99/Tc-99m that can be used for our educational and researchendeavors involving our pharmacy students. It will further benefit our studentsas they work through our nuclear pharmacy curriculum.”
“Because the RadioGenix System uses non-uranium basedmolybdenum-99 (Mo-99), it ensures that radiopharmacies can have stable,reliable access to domestically produced Mo-99 to produce Tc-99m,” said StephenMerrick, President and CEO of NorthStar Medical Radioisotopes. “This in turnenables reliable scheduling of procedures to meet patients’ healthcare needs ina timely manner.”
